Roche's Research Capabilities and Smart Pricing Offer an Advantage in the Pharmaceutical Market

Following the news that Roche Holdings (OTCMKTS:RHHBY) saw a 6% increase in revenues in the second quarter, Forbes assessed why Roche Holdings continues to grow while other pharmaceutical companies are limited by the impact of the patent cliff.
According to the article:

We believe Roche’s success is an amalgamation of strong research capabilities and smart pricing, which is all that’s needed to compete in the global pharmaceutical market. We see little downside to the stock considering Roche’s recent financial performance, its focus on broadly growing areas of oncology and immunology, and bubbling R&D pipeline. We are in the process of updating our price estimate for Roche Holdings in light of recent earnings and will have an update ready soon.

Click here to read Forbes’ full article on Roche Holdings.